Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
136.4 AUD | +0.22% |
|
-4.62% | +42.32% |
10/06 | Three companies to bet on medical AI | ![]() |
28/05 | Pro Medicus' US Subsidiary Signs Five New Contracts Worth at Least AU$45 Million | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- With an expected P/E ratio at 178.65 and 134.88 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+42.32% | 9.46B | C- | ||
+33.70% | 4.36B | B- | ||
-40.24% | 2.21B | C- | ||
-9.44% | 1.63B | - | C+ | |
-28.89% | 1.2B | B | ||
-43.71% | 974M | - | ||
-10.86% | 936M | C | ||
-47.63% | 739M | - | ||
-31.84% | 581M | - | ||
0.00% | 546M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PME Stock
- Ratings Pro Medicus Limited